Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $470000.0.

  • BridgeBio Pharma's Capital Expenditures rose 24306.57% to $470000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 1589.7%. This contributed to the annual value of $933000.0 for FY2024, which is 2856.05% down from last year.
  • Latest data reveals that BridgeBio Pharma reported Capital Expenditures of $470000.0 as of Q3 2025, which was up 24306.57% from $257000.0 recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Capital Expenditures registered a high of $6.5 million during Q3 2021, and its lowest value of $47000.0 during Q4 2024.
  • In the last 5 years, BridgeBio Pharma's Capital Expenditures had a median value of $470000.0 in 2025 and averaged $1.1 million.
  • Per our database at Business Quant, BridgeBio Pharma's Capital Expenditures skyrocketed by 107704.92% in 2021 and then crashed by 8919.54% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Capital Expenditures (Quarter) stood at $2.5 million in 2021, then tumbled by 68.41% to $801000.0 in 2022, then crashed by 45.69% to $435000.0 in 2023, then plummeted by 89.2% to $47000.0 in 2024, then surged by 900.0% to $470000.0 in 2025.
  • Its Capital Expenditures stands at $470000.0 for Q3 2025, versus $257000.0 for Q2 2025 and $337000.0 for Q1 2025.